<DOC>
	<DOCNO>NCT01098838</DOCNO>
	<brief_summary>The study evaluate safety increase dos oral LCL161 patient solid tumor . It primarily design evaluate side effect find maximum tolerate dose LCL161 .</brief_summary>
	<brief_title>Safety Efficacy LCL161 Patients With Solid Tumors</brief_title>
	<detailed_description />
	<criteria>Solid tumor ECOG performance status 02 Life expectancy great equal 12 week Must meet certain blood laboratory value Must meet criteria time since last dose prior therapy Must provide write informed consent participate study Active and/or symptomatic brain tumor brain metastasis . Patients unresolved nausea , vomit , diarrhea Any ongoing severe and/or uncontrolled medical condition could compromise participation study include heart , lung inflammatory disease Any disease may significantly alter absorption study drug ( example , ulcerative disease , uncontrolled nausea , vomit , diarrhea , malabsorption syndrome , removal small bowel ) Patients currently receive treatment steroid certain dose immunosuppressive treatment stop prior start study drug Patients currently receive treatment certain medication Patients receive radiation therapy undergone major surgery within last 4 week Women childbearing potential pregnant breast feeding . Known diagnosis human immunodeficiency virus ( HIV ) infection chronic active hepatitis B C Patients unwilling unable follow protocol Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Cancer</keyword>
	<keyword>adult</keyword>
	<keyword>solid tumor</keyword>
	<keyword>apoptosis</keyword>
	<keyword>program cell death</keyword>
	<keyword>LCL161</keyword>
</DOC>